Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-12T22:27:37.206Z Has data issue: false hasContentIssue false

Prescribing Approved Drugs for Nonapproved Uses: The Pharmacist’s Potential for Liability

Published online by Cambridge University Press:  27 April 2021

Extract

Drugs are frequently used for purposes not included in the manufacturers’ package inserts which are approved by the Federal Food and Drug Administration (FDA). A current example involves the industrial solvent dimethyl sulfoxide (DMSO), which is approved for human use only for the treatment of chronic interstitial cystitis, but is reportedly widely sold for the nonapproved purpose of arthritis treatment. The placing of this product in the pharmacy for sale to consumers could constitute the basis for an action by FDA against the pharmacy. This article will discuss the potential legal ramifications when a pharmacist dispenses an approved drug for a nonapproved use.

The question of a pharmacist’s liability for dispensing approved drugs for nonapproved uses has not yet been litigated. Courts have, however, held physicians liable for improperly prescribing drugs for nonapproved uses, as discussed by Professor Kapp in the preceding article. The premise of this article is that the pharmacist is potentially liable, and that the basis of this liability may be analogized to that of the physician’s liability.

Type
Article
Copyright
Copyright © American Society of Law, Medicine and Ethics 1981

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Uses of Drugs for Unapproved Indications: Your Legal Responsibility, FDA Drug Bulletin, pp. 2–3 (October 1972), reprinted in California Medicine 117:80 (1972), and Eye, Ear, Nose & Throat Monthly 51:69 (1972). See also United States v. Evers, note 2 infra, at 1149.Google Scholar
United States v. Evers, 453 F. Supp. 1141 (M.D. Ala., N.D. 1978).Google Scholar
Id. at 1149.Google Scholar
Kalzuny, E.L., Pharmacy Law Digest (Douglas-McKay, Inc.) (1978) at 457.Google Scholar
21 U.S.C. §353(b)(2).Google Scholar
Kalzuny, , supra note 4, at 460.Google Scholar
Mulder v. Parke Davis & Co., 181 N.W.2d 882, 887 (Minn. 1970).Google Scholar